NHS Could Save $135 Million A Year If Avastin Used in Eye Disease-Study

The UK’s publicly-funded National Health Service could save $135 million a year if it replaced a Novartis-marketed treatment for a common eye disease in elderly people with a cheaper, yet unapproved, rival drug from Roche, a new study found.
The Wall Street Journal